Jane Pritchett Henderson

Jane Pritchett Henderson has served as Apogee Therapeutics’ chief financial officer since January 2023. Ms. Henderson has an extensive track record of financial and corporate strategy leadership, including financing private and public companies, partnering and M&A, and building teams and operations. She has a combination of corporate, board and investment banking experience growing public and private biopharmaceutical companies. Prior to joining Apogee Therapeutics, Ms. Henderson has held executive level roles in finance and corporate development at numerous biotechnology companies, including Adagio Therapeutics, Turnstone Biologics, Voyager Therapeutics, Kolltan Pharmaceuticals (acquired by Celldex) and ISTA Pharmaceuticals (acquired by Bausch + Lomb). In addition to her industry experience, Ms. Henderson’s extensive healthcare investment banking experience includes the execution of more than 95 mergers and acquisitions, and advisory and financing deals as managing director and other senior roles at HSBC Holdings plc, Canadian Imperial Bank of Commerce, Lehman Brothers and Salomon Brothers. Ms. Henderson holds a B.S. in psychology from Duke University and currently serves on the board of directors of several companies including Akero Therapeutics, Inc. since April 2019, and IVERIC bio, Inc. since January 2018.